Genetic testing

American Kidney Fund and Alonzo Mourning Call for More Awareness and Understanding of APOL1-Mediated Kidney Disease (AMKD) on Capitol Hill

Retrieved on: 
Tuesday, April 9, 2024
American Kidney Fund, African Americans, Health, Apolipoprotein L1, L1, APOL1, Genetic testing, Disease, Risk, Policy, Black, Kidney disease, Vertex Pharmaceuticals, AKF, Pharmaceutical industry

ROCKVILLE, Md., April 09, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and basketball Hall-of-Famer Alonzo Mourning are teaming up on Capitol Hill for a roundtable and policy discussion to highlight the stories of people with APOL1-mediated kidney disease (AMKD) and spread awareness of this rapidly progressive form of genetic kidney disease.

Key Points: 
  • ROCKVILLE, Md., April 09, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and basketball Hall-of-Famer Alonzo Mourning are teaming up on Capitol Hill for a roundtable and policy discussion to highlight the stories of people with APOL1-mediated kidney disease (AMKD) and spread awareness of this rapidly progressive form of genetic kidney disease.
  • The roundtable is being held in conjunction with the nation’s first ever AMKD Awareness Day , which AKF is launching on April 30, 2024.
  • “For many years, I have publicly shared my personal kidney disease story to help educate people about APOL1-mediated kidney disease,” said Mourning.
  • Also participating in the roundtable discussion are:
    Support for AMKD Awareness Day activities, including this roundtable discussion, is provided by Vertex Pharmaceuticals Incorporated.

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Retrieved on: 
Tuesday, April 9, 2024
MYGN, Genetics, Overalls, Medicine, Patient, Myriad Genetics, Cohort (statistics), Genetic testing, DSM-IV codes, Pharmaceutical industry

(NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test .

Key Points: 
  • (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test .
  • “We are encouraged by the initial results of this study that showed how the proportion of patients with hospitalizations was significantly reduced after GeneSight testing,” said Dale Muzzey, chief scientific officer, Myriad Genetics.
  • We expect to share additional study results later this year.”
    The study demonstrated that the percentage of patients with hospitalizations was significantly reduced 180 days after GeneSight testing:
    39% relative reduction in psychiatric-related hospitalizations.
  • Significant reduction in hospitalizations for patients who were switched to a medication with no or moderate gene-drug interactions.

EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”

Retrieved on: 
Monday, April 8, 2024
Community, Genomics, Health, Genetic testing, GTG, Partnership, Knowledge, ASX, Security (finance), Risk, Krystal Barter, Woman, Risk assessment, Heart, Movement, BRCA1, Writing, Nursing

"Know Your Risk" is a movement towards empowering every woman with the knowledge to take charge of her health.

Key Points: 
  • "Know Your Risk" is a movement towards empowering every woman with the knowledge to take charge of her health.
  • Community Support: Be part of the launch of a "Know Your Risk" campaign, fostering a supportive community focused on empowering women to make informed decisions about their health.
  • Together with Humanise Health, a leading patient advocacy agency, we are at the forefront of advocating for preventative health and personalized health strategies.
  • This partnership for the "Know Your Risk" event underscores our collective dedication to empowering women with the knowledge to proactively manage their health.

Announcement Execution of Memorandum of Understanding for Share Acquisition (Subsidiarization)

Retrieved on: 
Wednesday, April 3, 2024
MOU, Target, Genetic testing, Relaxation, Fetus, Acquisition, Outline, Test management, Woman, Disorder, Transaction, Security (finance)

The Target Company is a company engaged in a prenatal diagnosis business providing genetic testing and analysis services.

Key Points: 
  • The Target Company is a company engaged in a prenatal diagnosis business providing genetic testing and analysis services.
  • We believe that business synergies will be generated as we aim to improve the value of the customer experience.
  • This acquisition is in line with our ongoing strategy of obtaining assets which can contribute to expanding our presence in Japan.
  • Making the Target Company our subsidiary by purchase of shares (cash settlement), share exchange (kabushiki koukan) or other methods, or a combination thereof.

Gattaca Genomics Partners with Ibanera to Revolutionize Digital Banking for Family Planning Innovation

Retrieved on: 
Tuesday, March 26, 2024
Partnership, Medicine, Genetic testing, Genetics, AI

Medical institutions worldwide can now leverage Gattaca Genomics' unparalleled expertise in genetic research and diagnostics, complemented by the embedded payment and financial services provided by Ibanera’s advanced technologies.

Key Points: 
  • Medical institutions worldwide can now leverage Gattaca Genomics' unparalleled expertise in genetic research and diagnostics, complemented by the embedded payment and financial services provided by Ibanera’s advanced technologies.
  • This alliance underscores a shared commitment to innovation, excellence, and client-centric services, uniting Gattaca’s genetic innovation with Ibanera’s digital banking prowess, ensuring smoother financial processes for healthcare innovations.
  • Michael Carbonara, CEO of both Gattaca Genomics and Ibanera, expresses his enthusiasm for the partnership, affirming, "Our journey at Ibanera to provide Banking-as-a-Service has reached new heights through our collaboration with Gattaca Genomics.
  • With both innovation and family values as our guiding principles, we are thrilled to support Gattaca’s pioneering strides in leveraging AI for family planning by facilitating seamless banking and payment processes."

CancerIQ CEO Feyi Ayodele Named to Modern Healthcare’s 2024 Innovators List

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Health, Technology, Hospitals, Genetics, Software, Genomics, Organization, Genetic testing, Risk, Patient, Mortality, AI, Risk assessment, Moonshot, Breast cancer, Multimedia, Pharmaceutical industry

CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of the Innovators for 2024 expanding access to genetically informed cancer prevention, early detection and treatment.

Key Points: 
  • CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of the Innovators for 2024 expanding access to genetically informed cancer prevention, early detection and treatment.
  • The profiles of the honorees are featured in the April 8, 2024 issue of MH magazine and online at ModernHealthcare.com/Innovator-Awards .
  • “The role of innovation has always been paramount in healthcare, and our 2024 honorees as top Innovators are driving real change in the industry,” said Mary Ellen Podmolik, editor in chief of Modern Healthcare.
  • She has driven adoption of the platform across 225 diverse clinical locations and specialties to make a direct patient impact.

Hartwig and Ultima Genomics Collaborate to Reduce Costs for Whole Genome Cancer Profiling, Minimal Residual Disease Testing and Generating Genetic Data at Scale

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Medical Devices, Health, Genetics, Oncology, Database, Genetic testing, Disease, Patient, NGS, Research, Cancer, Ultima, Architecture, MRD, Medical foundation, Hartwig, Blood, SNV, Medical imaging

This collaboration aims to reduce test costs and make complete genome-based cancer diagnostics accessible for more patients to have better informed cancer treatment.

Key Points: 
  • This collaboration aims to reduce test costs and make complete genome-based cancer diagnostics accessible for more patients to have better informed cancer treatment.
  • In parallel, platform strengths will be explored for minimal residual disease detection in blood of cancer patients with a one-size-fits-all solution that builds on pre-existing complete tumor profile information.
  • “Collaborating with Hartwig to deploy our technology toward whole genome cancer profiling, MRD testing and generating genomic information at scale is an exciting milestone,” said Gilad Almogy, CEO of Ultima Genomics.
  • Furthermore, lower costs can enable Hartwig to affordably create genetic datasets at national population scale to improve cancer research and ultimately outcomes for future patients.

GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Retrieved on: 
Monday, March 25, 2024
Ovarian cancer, Health, Comprehensive, Cardiovascular disease, Gene, Genetic testing, DSM-IV codes, Risk, Patient, HBOC, Breast, Risk assessment, Publication, Cancer, Breast cancer, Physician, Vaccine

Oncology, Cardiovascular, and Metabolic Disease Coverage: GeneType's Comprehensive Risk Assessment Test covers a diverse range of diseases, providing physicians and patients with a complete understanding of an individual's risk profile.

Key Points: 
  • Oncology, Cardiovascular, and Metabolic Disease Coverage: GeneType's Comprehensive Risk Assessment Test covers a diverse range of diseases, providing physicians and patients with a complete understanding of an individual's risk profile.
  • With an increasing emphasis on personalized medicine and preventative healthcare, the demand for comprehensive genetic risk assessments is expected to grow significantly.
  • GENE’s CEO Simon Morriss, commented “As pioneers in risk assessment testing, we are thrilled to introduce our latest GeneType Comprehensive Risk Assessment Test.
  • The Comprehensive Risk Assessment Test marks a significant step towards realizing this vision, offering a transformative tool for healthcare providers and their patients.

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Retrieved on: 
Friday, March 22, 2024
MYGN, Diagnosis, Genetic testing, Patent, Combinatorics, Genetics, Patient, Neoplasm, Research, DNA, Myriad Genetics, Doctor of Philosophy, Oncology, Medicine, University, MD Anderson Cancer Center, MRD, Intellectual property, FDA, Estate (law), Pharmaceutical industry

U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.

Key Points: 
  • U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.
  • This method describes a key aspect of tumor-informed MRD assays that detect circulating tumor DNA (ctDNA) through sequencing.
  • Specifically, the patented method relates to the manner in which a sample is sufficiently enriched with ctDNA that it can be detected, if present, with high sensitivity and specificity.
  • “The 2016 filing date of this patent—at the advent of MRD development—highlights Myriad’s foresight about the potential role of tumor-derived cell-free DNA in the expanding field of cancer diagnostics,” said Paul J. Diaz, President and CEO, Myriad Genetics.

Gattaca Genomics Welcomes Dr. Gary Harton as Principal Scientific Advisor

Retrieved on: 
Thursday, March 21, 2024
Health, Genetic testing, Entrepreneurship, Biotechnology, Genetics, University, Doctor of Philosophy, Genomics

Florida, March 21, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics , a leader in reproductive health and genetic testing services, is proud to announce the appointment of Dr. Gary L. Harton, PhD, as a consultant and Principal Scientific Advisor.

Key Points: 
  • Florida, March 21, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics , a leader in reproductive health and genetic testing services, is proud to announce the appointment of Dr. Gary L. Harton, PhD, as a consultant and Principal Scientific Advisor.
  • Gary Harton, with a PhD from the University of Kent and a distinguished career spanning several leading genetics and reproductive health organizations, has joined Gattaca Genomics to enhance the company's scientific and research endeavours.
  • ", says Dr. Harton
    "We are incredibly fortunate to have Dr. Gary Harton join our team as a consultant and Principal Scientific Advisor.
  • “The entire Gattaca Genomics team looks forward to working with Dr. Harton and benefiting from his expertise and leadership.”